General Anesthesia

Correct Answer

B — Intravenous anesthetic agent

Rationale

Propofol is classified as an intravenous anesthetic agent. It is administered by intravenous injection or infusion and is the most widely used intravenous agent for the induction and maintenance of general anesthesia. Volatile halogenated anesthetic agents — such as isoflurane, sevoflurane, desflurane, halothane, and enflurane — are liquids that vaporize for inhalational delivery. Nitrous oxide is an inhaled anesthetic gas stored as a liquid under pressure. Barbiturate anesthetic agents, such as thiopental, belong to a distinct chemical class characterized by the barbituric acid ring structure; propofol is a phenol derivative (2,6-diisopropylphenol), not a barbiturate.

Correct Answer

A — Serotonin type 3 receptor antagonist

Rationale

Ondansetron is classified as a serotonin type 3 receptor antagonist. It is used for prevention and treatment of postoperative nausea and vomiting and is typically administered near the end of surgery. Dopamine D2 receptor antagonists used as antiemetics include droperidol and metoclopramide. Glucocorticoid receptor agonists used for antiemetic prophylaxis include dexamethasone. Muscarinic cholinergic receptor antagonists used in the perioperative setting include glycopyrrolate, atropine, and scopolamine, which target different receptor systems and serve different clinical roles.

Correct Answer

C — Dopamine D2 receptor antagonist

Rationale

Droperidol is classified as a dopamine D2 receptor antagonist. It exerts its antiemetic effect at the chemoreceptor trigger zone (a region in the brainstem involved in initiating the vomiting reflex) and carries a United States Food and Drug Administration black box warning for QT interval prolongation and risk of torsades de pointes (a potentially life-threatening ventricular arrhythmia). Serotonin type 3 receptor antagonists used as perioperative antiemetics include ondansetron. Glucocorticoid receptor agonists used for antiemetic prophylaxis include dexamethasone. Muscarinic cholinergic receptor antagonists used in the perioperative period include glycopyrrolate, atropine, and scopolamine.

Correct Answer

A — Quaternary ammonium anticholinergic agent

Rationale

Glycopyrrolate is classified as a quaternary ammonium anticholinergic agent. Its quaternary ammonium structure (a nitrogen atom carrying four carbon substituents and a permanent positive charge) prevents it from crossing the blood-brain barrier, making it free of central nervous system anticholinergic effects. This distinguishes it from tertiary amine anticholinergic agents such as atropine and scopolamine, which do cross the blood-brain barrier and can produce central effects including sedation and confusion. Alpha-2 adrenergic receptor agonists used in anesthesia include dexmedetomidine and clonidine. Benzodiazepine receptor agonists used in the perioperative period include midazolam and diazepam.

Correct Answer

D — N-methyl-D-aspartate receptor antagonist

Rationale

Ketamine is classified as an N-methyl-D-aspartate receptor antagonist. The N-methyl-D-aspartate receptor is a subtype of glutamate receptor (the primary excitatory neurotransmitter receptor in the central nervous system) that plays a central role in pain transmission, memory, and consciousness. Ketamine's antagonism at this receptor produces a state called dissociative anesthesia. Gamma-aminobutyric acid type A receptor potentiators include propofol, etomidate, thiopental, and the benzodiazepines. Alpha-2 adrenergic receptor agonists used in anesthesia include dexmedetomidine. Mu-opioid receptor agonists used in the perioperative setting include fentanyl, morphine, and remifentanil.

Correct Answer

B — Benzodiazepine

Rationale

Midazolam is classified as a benzodiazepine. It is the standard perioperative benzodiazepine, used for preanesthetic anxiolysis, anterograde amnesia (prevention of new memory formation), and reduction of anesthetic agent requirements. Barbiturate anesthetic agents include thiopental, which shares the barbituric acid ring structure and acts at the gamma-aminobutyric acid type A receptor by a distinct mechanism from benzodiazepines. Phenol derivative intravenous anesthetics include propofol (2,6-diisopropylphenol). Alpha-2 adrenergic receptor agonists used in anesthesia include dexmedetomidine, which produces sedation and analgesia through a mechanism entirely distinct from the gamma-aminobutyric acid type A system.

Correct Answer

C — Potentiation of gamma-aminobutyric acid type A receptor-mediated chloride conductance

Rationale

Propofol produces anesthesia by potentiating the gamma-aminobutyric acid type A receptor, a ligand-gated chloride ion channel that mediates inhibitory neurotransmission throughout the central nervous system. By enhancing chloride conductance and hyperpolarizing neurons, propofol suppresses cortical and subcortical circuits responsible for consciousness. This same mechanism is shared by etomidate, thiopental, and the benzodiazepines, though each binds at distinct sites on the receptor complex. N-methyl-D-aspartate glutamate receptor antagonism is the primary mechanism of ketamine and nitrous oxide. Mu-opioid receptor agonism is the mechanism of opioid analgesics such as fentanyl and remifentanil, which contribute analgesia to balanced anesthesia but do not produce unconsciousness as their primary effect. Alpha-2 adrenergic receptor activation in the locus coeruleus (a noradrenergic nucleus in the brainstem) is the mechanism of dexmedetomidine-induced sedation.

Correct Answer

A — Inhibition of 11-beta-hydroxylase, blocking the final step of cortisol synthesis

Rationale

Etomidate suppresses adrenocortical function by inhibiting 11-beta-hydroxylase, the enzyme responsible for converting 11-deoxycortisol to cortisol in the final step of cortisol biosynthesis in the adrenal cortex. A single induction dose suppresses cortisol production for 6 to 24 hours. In healthy elective surgical patients this transient suppression is clinically insignificant, but in patients with septic shock — where adrenal reserve may already be compromised — even brief adrenal suppression may worsen outcomes, leading many centers to avoid etomidate in this population. Etomidate does not block adrenocorticotropic hormone receptors, suppress corticotropin-releasing hormone secretion from the hypothalamus, or directly damage adrenal cortex cells — it acts specifically at the enzymatic level within the steroidogenesis pathway.

Correct Answer

D — Central sympathetic nervous system stimulation with release of endogenous catecholamines

Rationale

Ketamine's sympathomimetic cardiovascular effects result from central stimulation of the sympathetic nervous system, leading to release of endogenous catecholamines (epinephrine and norepinephrine) from adrenal and sympathetic nerve terminals. This raises heart rate, systemic vascular resistance, cardiac output, and mean arterial pressure — the opposite of the cardiovascular depression produced by propofol, etomidate, and the barbiturates. This profile makes ketamine the induction agent of choice for hemodynamically unstable patients, including those in hemorrhagic shock. Ketamine does not directly stimulate cardiac beta-1 adrenergic receptors as its primary mechanism. Muscarinic receptor blockade causing tachycardia is the mechanism of atropine and glycopyrrolate, not ketamine. Baroreceptor-mediated reflex tachycardia from peripheral vasodilation is the mechanism seen with isoflurane and sevoflurane, where blood pressure falls before heart rate rises as a compensatory response — the opposite sequence from ketamine, which raises both simultaneously.

Correct Answer

B — Nitrous oxide contributes its own anesthetic potency, allowing a lower concentration of isoflurane to achieve the same depth of anesthesia

Rationale

Because minimum alveolar concentration (the alveolar concentration that prevents purposeful movement in 50% of patients at one atmosphere) values add directly across agents, 0.5 minimum alveolar concentration of nitrous oxide combined with 0.5 minimum alveolar concentration of isoflurane produces an effect equivalent to 1.0 minimum alveolar concentration of a single agent. This allows the required concentration of the volatile halogenated agent to be reduced, lowering the dose-dependent cardiovascular and respiratory depression associated with the more potent volatile agent. Nitrous oxide does not alter the blood:gas partition coefficient of co-administered agents — it influences alveolar partial pressure rise through the concentration effect and second gas effect, which are separate phenomena. Nitrous oxide does not inhibit isoflurane metabolism. The interaction is pharmacodynamic addition, not receptor-level displacement or synergy beyond simple additivity.

Correct Answer

A — Poor solubility in blood allows alveolar partial pressure to rise rapidly, accelerating equilibration with the brain

Rationale

The blood:gas partition coefficient describes how readily an inhalational anesthetic dissolves in blood relative to alveolar gas. An agent with a low coefficient is poorly soluble in blood, so blood does not act as a large reservoir requiring filling before alveolar partial pressure can rise. Alveolar partial pressure therefore climbs quickly, the brain equilibrates with the alveolus rapidly, and induction is fast. Desflurane (blood:gas coefficient approximately 0.42) and nitrous oxide (approximately 0.47) have the lowest coefficients and the fastest inductions. Halothane (approximately 2.4) is highly soluble in blood, which continuously removes agent from the alveolus, slowing the rise in alveolar partial pressure and producing the slowest induction. The blood:gas coefficient is a measure of blood solubility, not lipid solubility — lipid solubility (oil:gas coefficient) determines receptor potency. Cardiac output affects the rate of blood uptake from the alveolus but is a separate determinant of induction speed, not a property of the agent itself.

Correct Answer

C — Dexmedetomidine acts at alpha-2 adrenergic receptors in the locus coeruleus, a noradrenergic pathway distinct from the gamma-aminobutyric acid type A-mediated respiratory centers

Rationale

Dexmedetomidine produces sedation by activating alpha-2 adrenergic receptors in the locus coeruleus (the brainstem's primary noradrenergic nucleus), reducing norepinephrine release and producing a sedated state that closely resembles natural sleep. Because this mechanism operates through a noradrenergic pathway rather than through gamma-aminobutyric acid type A receptor activation, it does not suppress the medullary respiratory centers in the manner of propofol, barbiturates, or benzodiazepines — all of which produce sedation through gamma-aminobutyric acid type A potentiation and cause dose-dependent respiratory depression. Dexmedetomidine is not a gamma-aminobutyric acid type A potentiator at any clinical dose. It does not act at N-methyl-D-aspartate receptors. It does not stimulate peripheral chemoreceptors — its preservation of respiratory drive is a consequence of its mechanism, not a compensatory reflex.

Correct Answer

B — Rapid diffusion of nitrous oxide from blood into the alveoli dilutes alveolar oxygen, transiently lowering alveolar oxygen partial pressure

Rationale

Diffusional hypoxia (also called the Fink effect) occurs because nitrous oxide is highly soluble in blood and accumulates in large quantities during anesthesia. When administration is stopped, this dissolved nitrous oxide rapidly diffuses back out of the blood into the alveoli. The outflux of this large volume of gas dilutes both alveolar oxygen and carbon dioxide, transiently reducing alveolar oxygen partial pressure to levels that can cause clinically significant hypoxemia. The effect is greatest in the first five to ten minutes after stopping nitrous oxide and is reliably prevented by administering 100% oxygen for several minutes before allowing the patient to breathe room air. Nitrous oxide does not displace oxygen from hemoglobin — that mechanism describes carbon monoxide toxicity. Nitrous oxide does not inhibit surfactant production. There are no pulmonary capillary binding sites for which gases compete.

Correct Answer

D — All volatile halogenated anesthetic agents are triggering agents for malignant hyperthermia and must be avoided entirely

Rationale

Malignant hyperthermia is a pharmacogenetic disorder caused primarily by mutations in the ryanodine receptor type 1 gene that render the sarcoplasmic reticulum calcium release channel pathologically sensitive to certain triggering agents. All volatile halogenated anesthetic agents — including halothane, isoflurane, sevoflurane, desflurane, and enflurane — are triggering agents that can precipitate an uncontrolled hypermetabolic crisis in susceptible patients. Because no volatile halogenated agent is safe in this population, total intravenous anesthesia using propofol, opioids, and nondepolarizing neuromuscular blocking agents is obligatory. Nitrous oxide is not a triggering agent for malignant hyperthermia and may be used, but it cannot produce surgical anesthesia alone (its minimum alveolar concentration exceeds 100% at atmospheric pressure) and is therefore not sufficient as a sole replacement for volatile agents. Propofol does not directly antagonize the ryanodine receptor — dantrolene is the specific antidote that stabilizes the ryanodine receptor in its closed state.

Correct Answer

C — Antagonism of serotonin type 3 receptors at vagal afferents and the chemoreceptor trigger zone

Rationale

Propofol's antiemetic properties are explained by its antagonism at serotonin type 3 receptors — the same receptor class targeted by ondansetron. The chemoreceptor trigger zone (a brainstem region that detects emetogenic signals in blood and cerebrospinal fluid) and vagal afferents in the gastrointestinal tract both use serotonin type 3 receptor signaling to initiate the vomiting reflex; blockade of these receptors reduces the emetic stimulus. This antiemetic property makes propofol-based total intravenous anesthesia the preferred maintenance technique in patients at high risk for postoperative nausea and vomiting, since volatile halogenated agents lack this benefit and increase emetic risk. Dopamine D2 receptor blockade at the chemoreceptor trigger zone is the mechanism of droperidol and metoclopramide — not propofol. Inhibition of prostaglandin synthesis is the mechanism of nonsteroidal anti-inflammatory drugs. Gamma-aminobutyric acid type A potentiation in the medulla explains propofol's anesthetic mechanism, not its antiemetic effect.

Correct Answer

A — Etomidate, because it produces minimal change in cardiac output, heart rate, and systemic vascular resistance

Rationale

Etomidate's defining clinical advantage is exceptional hemodynamic stability. Unlike propofol and thiopental — which reduce blood pressure through peripheral vasodilation and myocardial depression respectively — etomidate causes negligible change in cardiac output, heart rate, or systemic vascular resistance at induction doses. This makes it the preferred induction agent when cardiovascular reserve is severely compromised, as in cardiogenic shock, severe aortic stenosis, and cardiac tamponade. Propofol causes dose-dependent hypotension through peripheral vasodilation and modest myocardial depression, making it poorly tolerated in this setting. Thiopental similarly causes significant cardiovascular depression at induction doses. Midazolam at standard premedicant doses (1 to 2 mg) has minimal cardiovascular effects, but at the higher doses required for induction it also reduces blood pressure and is not reliable as a sole induction agent in this context. The major limitation of etomidate is adrenocortical suppression from 11-beta-hydroxylase inhibition, which persists for 6 to 24 hours after a single dose.

Correct Answer

B — Ketamine, because central sympathetic stimulation produces bronchodilation and maintains cardiovascular stability

Rationale

Ketamine is the induction agent of choice for emergency airway management in patients with acute severe asthma. Through central sympathetic nervous system stimulation and release of endogenous catecholamines, ketamine produces potent bronchodilation — directly opposing the bronchospasm that defines this patient's condition. Its sympathomimetic cardiovascular effects (increased heart rate, blood pressure, and cardiac output) also maintain hemodynamic stability, which may be compromised by severe bronchospasm and respiratory failure. Propofol does not have bronchodilator properties and causes dose-dependent hypotension, making it less suitable in this acute setting. Etomidate provides hemodynamic stability but lacks bronchodilator activity — hemodynamic stability alone does not address the underlying bronchospasm. Thiopental causes histamine release and can paradoxically worsen bronchospasm, making it contraindicated in patients with reactive airways disease.

Correct Answer

D — Enriching the alveolar gas with oxygen ensures that when nitrous oxide diffuses back from blood into the alveoli, it dilutes an oxygen-rich mixture rather than room air, preventing a critical fall in alveolar oxygen partial pressure

Rationale

Diffusional hypoxia (the Fink effect) occurs because large quantities of nitrous oxide dissolved in blood during anesthesia rapidly diffuse back into the alveoli when administration is stopped. This outflux of gas dilutes the remaining alveolar gases — including oxygen — and transiently lowers alveolar oxygen partial pressure to levels that can cause clinically significant hypoxemia. When the patient breathes 100% oxygen rather than room air, the alveolar oxygen concentration is already high before the nitrous oxide outflux begins. The same volume of nitrous oxide diffusing into an oxygen-enriched alveolus produces a much smaller fractional reduction in alveolar oxygen partial pressure, preventing the fall to hypoxemic levels. The effect is greatest in the first five to ten minutes after discontinuing nitrous oxide. Oxygen does not accelerate nitrous oxide elimination by mass action — the driving force for nitrous oxide elimination is the blood-to-alveolus partial pressure gradient, not competition with oxygen. Oxygen does not stimulate carotid body chemoreceptors in this context — high inspired oxygen actually suppresses hypoxic ventilatory drive. Nitrous oxide and oxygen do not compete for hemoglobin binding sites — that mechanism describes carbon monoxide, which binds hemoglobin with high affinity.